| Literature DB >> 33313143 |
Tao Wang1, Xianwei Yang1, Wanxiang Wang2, Tingyu Chen3, Junjie Kong1, Shu Shen1, Ying Chen4, Gengfu Wei5, Dinggang Yu6, Cong Wang7, Minghao Li8, Shaozhen Rui9, Biao Luo10, Wentao Wang1.
Abstract
BACKGROUND: Skeletal muscle depletion and excessive visceral adipose tissue have been shown to be independent risk factors for postoperative complications (PCs) in various diseases. However, their impact on surgical PCs in hepatic alveolar echinococcosis (HAE) is still unknown.Entities:
Keywords: Hepatic alveolar echinococcosis (HAE); least absolute shrinkage and selection operator (LASSO) logistic regression; postoperative complications; sarcopenia; visceral adiposity
Year: 2020 PMID: 33313143 PMCID: PMC7723579 DOI: 10.21037/atm-20-1960a
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1The flowchart of patient selection.
Figure 2Cross-sectional computed tomography (CT) images at the level of the third lumbar vertebra (L3). (A) Skeletal muscle areas are quantified using a CT attenuation value of –29 to 150 Hounsfield units (HU). (B) Visceral adipose tissue areas were quantified using attenuation values of –150 to –50 HU. (C) Subcutaneous adipose tissue areas were quantified using attenuation values of −190 to −30 HU. (D) The quality and myosteatosis of skeletal muscle were examined by intramuscular adipose tissue content (IMAC) at the L3 level. The CT values of subfascial muscular tissue in the multifidus muscle (2 circles) and subcutaneous fat (4 small circles) were examined to calculate IMAC.
Perioperative data
| Primary set (n=233) | Validation set (n=54) | |
|---|---|---|
| Age (years), median (range) | 40 (18–69) | 38.5 (19–68) |
| Gender (male/female) | 124/109 | 24/30 |
| BMI (kg/m2), median (range) | 22.14 (17.24–31.40) | 22.43 (19.12–35.55) |
| ASA score, median (range) | 2 (2–3) | 2 (2–3) |
| Liver cirrhosis, n, (%) | 44 (18.88%) | 10 (18.52%) |
| Preoperative HGB (g/L), median (range) | 134 (81–207) | 148 (83–179) |
| Preoperative RDW, median (range) | 14 (11.3–31.6) | 18.5 (11.1–31.2) |
| Preoperative WBC count, median (range) ×109/L | 6.64 (1.62–15.36) | 6.36 (3–11.5) |
| Preoperative NEUT count, median (range) ×109/L | 4.03 (1.17–11.51) | 4.03 (1.37–9.68) |
| Preoperative LYMPH count, median (range), ×109/L | 1.68 (0.2–4.46) | 1.46 (0.71–2.72) |
| Preoperative ES count, median (range), ×109/L | 0.29 (0–4.38) | 0.23 (0–2.29) |
| Preoperative PLT count, median (range), ×109/L | 245 (45–467) | 233.5 (89–432) |
| Preoperative ALT (U/L), median (range) | 25 (6–416) | 24.5 (8–386) |
| Preoperative AST (U/L), median (range) | 25 (11–424) | 24 (11–412) |
| Preoperative ALP (U/L), median (range) | 124 (16–1440) | 93.5 (49–889) |
| Preoperative GGT (U/L), median (range) | 62 (7–1,082) | 63.5 (11–1,067) |
| Preoperative LDH (U/L), median (range) | 177 (43–711) | 164 (43–516) |
| Preoperative Total bilirubin (μmol/L), median (range) | 9.7 (2.9–232.5) | 9.5 (3.8–178.2) |
| Preoperative ALB (g/L), median (range) | 39.4 (26.5–52.2) | 38.4(30.7–45.1) |
| Preoperative creatinine, mg/dL, median (range) | 0.69(0.27–1.24) | 0.70(0.32–1.27) |
| Preoperative PT(s) | 12.4 (10–26.7) | 12.8 (10.1–15.8) |
| Preoperative INR, median (range) | 1.07 (0.85–1.67) | 1.09 (0.9–1.32) |
| NLR, median (range) | 2.42 (0.48–19.78) | 2.73 (0.88–8.34) |
| ALBI, median (range) | −2.72 (−3.78–−0.85) | −2.53 (−3.29–−1.41) |
| AGR, median (range) | 1.10 (0.38–2.69) | 1.03 (0.62–2.20) |
| Lesion size (cm), median (range) | 9.6 (1.8–22) | 8.9 (3.8–19.6) |
| Lesion number (multiple/solitary) | 64/169 | 16/38 |
| Surface area of hepatectomy (major/minor) | 143/90 | 25/29 |
| Macroscopic vascular invasion (yes/no) | 97/136 | 28/26 |
| Adrenal invasion, n (%) | 28 (12.02) | 12 (22.22) |
| Diaphragm invasion, n (%) | 74 (31.76) | 15 (27.78) |
| Bile duct invasion, n (%) | 44 (18.88) | 8 (14.81) |
| PMI, cm2/m2, median (range) | 6.21 (1.75–12.84) | 5.10 (1.81–10.9) |
| SMI, cm2/m2, median (range) | 42.76 (23.88–67.16) | 42.14 (25.09–67.52) |
| VSR, cm2/cm2, median (range) | 0.35 (0.05–2.90) | 0.28 (0.07–2.34) |
| IMAC, median (range) | −0.54 (–1.89–−0.06) | −0.62 (−1.18–−0.23) |
| Surgical approach (LLR/OLR) | 11/222 | 1/53 |
| Transfusion (yes/no) | 54/179 | 15/39 |
| PNM stage (early stage/late stage) | 154/79 | 34/20 |
| Hospital stay (days) | 12 (6–66) | 23.5 (14–45) |
| Postoperative complication (Clavien-Dindo ≥3) | 42 (18.02%) | 13 (24.07%) |
| Postoperative 90-day mortality | 4 (1.72%) | 1 (1.85%) |
BMI, body mass index; ASA, American Society of Anesthesiology; HGB, hemoglobin; RDW, Red blood cell distribution width; WBC, white blood cell; NEUT, neutrophil; LYMPH, lymphocyte: MONO, Monocyte; ES, eosinophil; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase; LDH, lactate dehydrogenase; PT, Prothrombin time; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte; ALBI grade, albumin-bilirubin grade; AGR, albumin/globulin ratio; LLR, laparoscopic liver resection; OLR, open liver resection; PMI, psoas muscle mass index; SMI, Skeletal muscle mass index; VSR, visceral to subcutaneous adipose tissue area radio; IMAC, intramuscular adipose tissue content.
Figure 3(A) The least absolute shrinkage and selection operator (LASSO) coefficient profiles of the five selected sarcopenia features. A dashed vertical line is drawn at the value (logγ =−4.3) chosen by 10-fold cross-validation. (B) Partial likelihood deviance for the LASSO coefficient profiles. A light dashed vertical line stands for the minimum partial likelihood deviance. A dashed vertical line stands for the partial likelihood deviance at the value (logγ =−4.3).
Demographics and clinicopathologic characteristics of patients with HAE according to type of sarcopenia score
| Variable | Primary set (n=233) | Validation set (n=54) | |||||
|---|---|---|---|---|---|---|---|
| Sarcopenia type A (n=63) | Sarcopenia type B (n=170) | P value | Sarcopenia type A (n=20) | Sarcopenia type B (n=34) | P value | ||
| Age, years, median (range) | 42 (20–65) | 40 (18–69) | 0.508 | 36.5 (22–53) | 41 (19–68) | 0.496 | |
| Sex, male/female | 19/44 | 105/65 | <0.001 | 7/13 | 17/17 | 0.284 | |
| BMI, kg/m2 | 21.77 (17.24–31.4) | 22.15 (17.36–31.11) | 0.098 | 22.26 (19.12–33.41) | 22.61 (19.65–35.55) | 0.802 | |
| ASA score | 2 (2–3) | 2 (2–3) | 0.368 | 2 (2–3) | 2 (2–3) | 0.236 | |
| Liver cirrhosis (by image study), n (%) | 8 (12.70) | 36 (21.18) | 0.142 | 4 (20) | 6 (17.65) | 0.830 | |
| Baseline laboratory investigations | |||||||
| Preoperative HGB (g/L), median (range) | 130 (81–201) | 137.5 (83–207) | 0.006 | 148 (83–179) | 147.5 (118–179) | 0.320 | |
| Preoperative RDW, median (range) | 14.2 (12.1–31.6) | 13.9 (11.3–29.3) | 0.126 | 19.6 (12.8–30.7) | 15.75 (11.7–31.2) | 0.754 | |
| Preoperative WBC count, median (range) ×109/L | 6.07 (1.62–10.06) | 6.745 (3.52–15.36) | 0.017 | 5.875 (3.5–11.5) | 6.95 (3–11.4) | 0.090 | |
| Preoperative NEUT count, median (range) ×109/L | 3.86 (1.17–9.76) | 4.065 (1.73–11.51) | 0.245 | 3.62 (1.63–9.68) | 4.68 (1.37–9.10) | 0.065 | |
| Preoperative LYMPH count, median (range), ×109/L | 1.63 (0.2–2.52) | 1.69 (0.45–4.46) | 0.538 | 1.48 (0.83–2.15) | 1.39 (0.71–2.72) | 0.936 | |
| Preoperative ES count, median (range), ×109/L | 0.29 (0.01–4.38) | 0.3 (0.00–3.17) | 0.865 | 0.22 (0–2.18) | 0.26 (0.01–2.29) | 0.809 | |
| Preoperative PLT count, median (range), ×109/L | 268 (67–463) | 234.5 (45–467) | 0.128 | 247.5 (89–371) | 218.5 (98–432) | 0.380 | |
| ALT (U/L), median (range) | 21 (9–171) | 26 (6–416) | 0.276 | 28.5 (11–320) | 23 (8–386) | 0.220 | |
| AST (U/L), median (range) | 24 (13–287) | 25 (11–424) | 0.711 | 28.5 (15–337) | 21 (11–412) | 0.053 | |
| ALP (U/L), median (range) | 114 (46–814) | 125 (16–1,440) | 0.943 | 106.5 (57–713) | 90.5 (49–889) | 0.237 | |
| GGT (U/L), median (range) | 60 (9–1,082) | 62.5 (7–1,067) | 0.842 | 72.5 (16–667) | 63.5 (11–1,067) | 0.154 | |
| LDH (U/L), median (range) | 177 (43–314) | 176 (62–711) | 0.694 | 174.5 (43–516) | 153.5 (45–312) | 0.061 | |
| Total bilirubin (μmol/L), median (range) | 7.8 (2.9–93.5) | 10.15 (3–232.5) | 0.036 | 11.75 (4–106.4) | 8.55 (3.8–178.2) | 0.130 | |
| Direct bilirubin (μmol/L), median (range) | 3.6 (1.3–91.8) | 4.1 (0.9–182.7) | 0.092 | 5.7 (2.3–78.9) | 3.8 (1.5–126.2) | 0.338 | |
| ALB (g/L), median (range) | 39.1 (29.2–45.3) | 39.55 (26.5–52.2) | 0.138 | 38.25 (31.1–42.9) | 38.75 (30.7–45.1) | 0.560 | |
| Creatinine, mg/dL, median (range) | 0.64 (0.27–1.10) | 0.71 (0.27–1.24) | 0.250 | 0.76 (0.41–1.27) | 0.68 (0.32–1.14) | 0.263 | |
| PT (s), median (range) | 12.1 (10.4–26.7) | 12.4 (10–18.3) | 0.369 | 12.95 (11.1–15.8) | 12.6 (10.1–15.6) | 0.380 | |
| INR, median (range) | 1.05 (0.85–1.39) | 1.07 (0.85–1.67) | 0.932 | 1.095 (0.97–1.32) | 1.09 (0.90–1.26) | 0.823 | |
| NLR, median (range) | 2.37 (0.76–11.09) | 2.42 (0.48–19.78) | 0.770 | 2.59 (1.32–8.34) | 3.16 (0.88–7.71) | 0.103 | |
| ALBI, median (range) | −2.66 (–3.24 to −1.64) | −2.72 (−3.78 to −0.85) | 0.470 | −2.47 (−3.14 to −1.87) | −2.61 (−3.29 to −1.41) | 0.119 | |
| AGR, median (range) | 1.07 (0.44–1.93) | 1.11 (0.38–2.69) | 0.175 | 1.07 (0.73–1.79) | 0.98 (0.62–2.20) | 0.191 | |
| Lesion location, n (%) | 0.926 | 0.403 | |||||
| Right lobe | 35 (55.56) | 90 (52.94) | 12 (60.0) | 25 (73.53) | |||
| Left lobe | 11 (17.46) | 30 (17.65) | 2 (10.0) | 4 (11.76) | |||
| Both lobes | 17 (26.98) | 50 (29.41) | 6 (30.0) | 5 (14.71) | |||
| Maximum lesion size, cm, n (%) | 9.7 (3–17.1) | 9.5 (1.8–22) | 0.844 | 10.2 (5.5–19.6) | 8.4 (3.8–16.1) | 0.457 | |
| Lesion number, n (%) | 0.275 | 0.071 | |||||
| Multiple | 14 (22.22) | 50 (29.41) | 3 (15.0) | 13 (38.24) | |||
| Solitary | 49 (77.78) | 120 (70.59) | 17 (85.0) | 21 (61.76) | |||
| Surface area of hepatectomy, n (%) | |||||||
| Major | 38 (60.32) | 105 (61.76) | 0.840 | 11 (55.0) | 14 (41.18) | 0.325 | |
| Minor | 25 (39.68) | 65 (38.24) | 9 (45.0) | 20 (58.82) | |||
| Macroscopic vascular invasion, n (%) | 0.817 | 0.138 | |||||
| Yes | 27 (42.86) | 70 (41.18) | 13 (65.0) | 15 (44.12) | |||
| No | 36 (57.14) | 100 (58.82) | 7 (35.0) | 19 (55.88) | |||
| Adrenal invasion, n (%) | 0.796 | 0.083 | |||||
| Yes | 7 (11.11) | 21 (12.35) | 7 (35.0) | 5 (14.71) | |||
| No | 56 (88.89) | 149 (87.65) | 13 (65.0) | 29 (85.29) | |||
| Diaphragm invasion, n (%) | |||||||
| Yes | 15 (23.81) | 59 (34.71) | 0.113 | 7 (35.0) | 8 (23.53) | 0.363 | |
| No | 48 (76.19) | 111 (65.29) | 13 (65.0) | 26 (76.47) | |||
| Bile duct invasion, n (%) | 0.122 | ||||||
| Yes | 16 (25.40) | 28 (16.47) | 5 (25.0) | 3 (8.82) | 0.106 | ||
| No | 47 (74.60) | 142 (83.53) | 15 (75.0) | 31 (91.18) | |||
| PMI, cm2/m2 | 4.18 (1.75–8.92) | 7.04 (3.8–12.84) | <0.001 | 3.45 (1.81–6.02) | 5.73 (2.5–10.90) | <0.001 | |
| SMI, cm2/m2 | 37.02 (23.88–58.16) | 45.01 (28.30–67.16) | <0.001 | 30.38 (25.09–51.91) | 48.07 (30.87–67.52) | <0.001 | |
| VSR, cm2/cm2 | 0.40 (0.05–2.90) | 0.32 (0.05–1.45) | 0.026 | 0.52 (0.21–2.34) | 0.23 (0.07–1.1) | 0.013 | |
| IMAC | −0.51 (−1.12 to −0.95) | −0.56 (−1.89 to −0.06) | <0.001 | −0.47 (−1.14 to −0.23) | −0.66 (−1.18 to −0.33) | <0.001 | |
| Surgical approach, n (%) | 0.297 | 0.370 | |||||
| Open | 1 (1.59) | 10 (5.88) | 19 (95.0) | 34 (100.0) | |||
| Laparoscopic | 62 (98.41) | 160 (94.12) | 1 (5.0) | 0 (0.0) | |||
| Transfusion, n (%) | 0.402 | 0.124 | |||||
| Yes | 17 (26.98) | 37 (21.76) | 8 (40.0) | 7 (20.59) | |||
| No | 46 (73.02) | 133 (78.24) | 12 (60.0) | 27 (79.41) | |||
| PNM stage, n (%) | 0.259 | 0.666 | |||||
| P1N0–1M0 | 18 (28.57) | 63 (37.06) | 4 (20.0) | 4 (11.76) | |||
| P2N0–1M0 | 19 (30.16) | 54 (31.76) | 8 (40.0) | 18 (52.94) | |||
| P3N0–1M0 | 17 (26.98) | 27 (15.88) | 7 (35.0) | 9 (26.47) | |||
| P4N0–1M0 | 9 (14.29) | 26 (15.29) | 1 (5.0) | 3 (8.82) | |||
| Hospital stay (days) | 14 (7.0–66.0) | 11.5 (6.0–43.0) | 0.001 | 27 (18.0–45.0) | 23 (14.0–40.0) | 0.016 | |
| 90 days mortality, n (%) | 3 (4.76) | 1 (0.59) | 0.029 | 1 (5.0) | 0 (0.0) | 0.370 | |
BMI, body mass index; ASA, American Society of Anesthesiology; HGB, hemoglobin; RDW, red blood cell distribution width; WBC, white blood cell; NEUT, neutrophil; LYMPH, lymphocyte: MONO, monocyte; ES, eosinophil; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase; LDH, lactate dehydrogenase; PT, prothrombin time; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte; ALBI grade, albumin-bilirubin grade; AGR, albumin/globulin ratio; LLR, laparoscopic liver resection; OLR, open liver resection; PMI, psoas muscle mass index; SMI, Skeletal muscle mass index; VSR, visceral to subcutaneous adipose tissue area radio; IMAC, intramuscular adipose tissue content.
Logistic regression models of variables associated major postoperative complications
| Variable | Univariate regression model | Multivariate regression model | |||||
|---|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | P value | Odds ratio | 95% CI | P value | ||
| Age (≥40 | 0.777 | 0.398–1.516 | 0.459 | 0.858 | 0.405–1.819 | 0.690 | |
| Sex (female | 2.114 | 1.066–4.196 | 0.032 | 2.041 | 0.937–4.445 | 0.073 | |
| Liver cirrhosis (yes | 1.443 | 0.648–3.215 | 0.370 | ||||
| Preoperative ES (≥0.425 | 2.537 | 1.283–5.017 | 0.007 | 1.225 | 0.527–2.848 | 0.637 | |
| Preoperative ALP (≥164.5 | 2.720 | 1.376–5.378 | 0.004 | 1.085 | 0.442–2.663 | 0.859 | |
| Preoperative GGT (≥63.5 | 3.253 | 1.571–6.737 | 0.001 | 2.527 | 1.013–6.301 | 0.047 | |
| Preoperative LDH (≥186.5 | 2.646 | 1.339–5.228 | 0.005 | 1.782 | 0.801–3.966 | 0.157 | |
| Preoperative ALB (≤30 | 1.905 | 0.568–6.396 | 0.297 | ||||
| NLR (≥3.83 | 2.174 | 0.949–4.982 | 0.066 | ||||
| ALBI (≥−2.515 | 2.430 | 1.226–4.817 | 0.011 | 1.397 | 0.622–3.137 | 0.418 | |
| PNI (≤47 | 1.680 | 0.858–3.290 | 0.131 | ||||
| Scre/Scys (≥1.27 | 2.372 | 0.569–9.894 | 0.236 | ||||
| Maximum lesion size (>10 | 2.393 | 1.196–4.785 | 0.014 | 0.638 | 0.248–1.640 | 0.351 | |
| Lesion number (multiple | 0.567 | 0.247–1.302 | 0.181 | ||||
| Blood loss >500 mL | 0.993 | 0.951–1.036 | 0.736 | ||||
| Blood transfusion (yes | 2.165 | 1.051–4.460 | 0.036 | 1.351 | 0.582–3.135 | 0.484 | |
| Macroscopic vascular invasion (yes | 3.457 | 1.735–6.891 | <0.001 | 1.802 | 0.788–4.121 | 0.163 | |
| Bile duct invasion (yes | 1.987 | 0.921–4.291 | 0.080 | ||||
| Diaphragm invasion (yes | 0.832 | 0.399–1.735 | 0.624 | ||||
| Adrenal invasion (yes | 2.469 | 1.028–5.930 | 0.043 | 1.519 | 0.543–4.250 | 0.425 | |
| Surface area of hepatectomy (major | 3.630 | 1.895–11.705 | 0.001 | 3.210 | 1.064–9.687 | 0.038 | |
ES, eosinophil; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase; LDH, lactate dehydrogenase; ALB, albumin; NLR, neutrophil-to-lymphocyte ratio; ALBI grade, albumin-bilirubin grade; PNI, prognostic nutrition index; Scre/Scys, serum creatinine/serum cystatin C.
Figure 4Preoperative assessment and surgical techniques. (A, B) A preoperative computed tomography (CT) scan showed a massive lesion of hepatic alveolar echinococcosis (HAE) occupying the left medial lobe and right anterior lobe, resulting in left hepatic bile duct dilation (black arrow). (C) A HAE lesion in the right liver involving the diaphragm (white arrow). (D) A HAE lesion invading liver parenchyma and biliary tract. After complete removal of the HAE lesion, then anastomosis of the biliary tract was performed (white arrow). (E) A HAE lesion invading the right posterior inferior vein of the liver. After complete removal of the HAE lesion, the right posterior inferior vein was reconstructed. (F) A larger surface area of liver resection after the HAE lesion was removed.
Figure 5Nomogram for predicting postoperative complications and calibration plot. (A) The nomogram maps the predicted probability of postoperative complications on a scale of 0 to 240. For each covariate, please draw a vertical line upwards and note down the corresponding points. This is repeated for each covariate ending with a total score that corresponds to a predicted probability of postoperative complication at the bottom of the nomogram. The calibration curve for predicting patient’s postoperative complications in the primary set (B) and in the validation set (C). Ideal line (blue), estimated probabilities correspond to the actual observed; apparent line (red), prediction capability of the model obtained after data analysis; bias-corrected line, prediction capability of the model obtained after bootstrap correction.
Figure 6The decision curves of the nomograms for predicting postoperative complications in the primary set and validation set are presented.